ArticleCell biochemistry and biophysics2026
Computational and Experimental Approaches for Development of Therapeutics Agents against Acute Pain from Heliotropium Indicum L.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, the Heliotropium indicum plant has been utilized in indigenous medicine to manage different health issues including asthma, coughs, bronchitis, skin disorders, wounds, and rheumatic pains. The purpose is to measure the comparative characteristics of H. indicum (MEHI) in terms of its pain-relieving properties by in vivo testing on mice and to conduct a quantitative phytochemicals analysis using mass spectrometer to screen out the most active compound through computational investigation. The pain-relieving properties of MEHI were analyzed through the nociceptive model, revealing a 78.80% (p < 0.001) decrease in pain sensitivity at 400 mg/kg doses. Apart from writhing response test, MEHI revealed a significant (57.86% inhibition at 400 mg/kg dose; p < 0.01) dose-dependent pain-relieving effect in both tail thermal pain sensitivity and formalin-evoked licking behavior test. Furthermore, quantum chemical calculations were conducted for atomic-level replication, orbital characteristics, and electrostatic potential to assess the dependability of the protein-drug complexes. Upon GC-MS analysis of MEHI, sixteen compounds were identified, with the primary components being ester and unsaturated fatty acids, and the results from the in vivo tests revealed significant dose-dependent response in pain relief and resembled those of standard drugs used, indicating a similar pain-relieving mechanism. Besides, molecular docking studies on the identified compounds revealed that 1,2,3,4-tetrahydro-3-(phenylacetamido) quinoline (C15) exhibited strong binding to COX-2, suggesting its potential in managing pain with improved pharmacokinetic and toxicological profiles compared to diclofenac. This study represents the first comprehensive quantum chemical evaluation of the molecular reactivity, atomic charges, thermodynamic properties, and molecular electrostatic potential (MEP) of the compounds identified from MEHI to evaluate their potential as reliable drug candidates. Clinical Trial. The authors confirm that this research is not associated with any clinical trial.
Indexed as
Identifiers
41493528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.